Baseline characteristics of the 1:1 propensity score–matched study cohorts
| . | Rivaroxaban, % . | LMWH, % . | Standardized difference . |
|---|---|---|---|
| Demographics | |||
| Age, median (25%, 75%), y* | 73 (68, 78) | 72 (68, 78) | — |
| Age ≥75 y | 42.2 | 40.6 | 0.0306 |
| Female sex | 74.7 | 71.3 | 0.0780 |
| White race | 80.2 | 80.7 | −0.0142 |
| Index event PE (with or without DVT) | 43.5 | 45.4 | −0.0381 |
| Index DVT only | 56.5 | 54.6 | 0.0381 |
| Primary cancer site | |||
| Breast | 36.9 | 35.0 | 0.0392 |
| Lung | 43.5 | 46.3 | −0.0572 |
| Ovary | 6.2 | 6.8 | −0.0235 |
| Pancreas | 10.2 | 8.7 | 0.0501 |
| Other | 3.2 | 3.2 | 0 |
| Cancer stage at diagnosis† | |||
| Stage, median (25%, 75%)* | 2 (2, 3) | 2 (2, 3) | — |
| Stage II or III | 98.9 | 0.0569 | |
| Stage I or IV or unknown | — | — | ‡ |
| Time from first cancer diagnosis to index VTE, y§ | |||
| Median (25%, 75%)* | 0.64 (0.13, 2.31) | 0.59 (0.13, 2.28) | — |
| <1 | 57.8 | 56.7 | 0.0229 |
| 1 to <2 | 13.0 | 14.6 | −0.045 |
| 2 to <3 | 9.5 | 7.8 | 0.0578 |
| ≥3 | 19.7 | 21.0 | −0.0331 |
| Comorbidities and medications | |||
| Active cancer therapy | 73.0 | 72.4 | 0.0128 |
| Antiplatelet use | 7.9 | 7.4 | 0.0208 |
| CKD stage 3 or worse | 32.5 | 32.9 | −0.0080 |
| Coagulopathy | 9.3 | 8.1 | 0.0392 |
| Major bleed | ‡ | ‡ | 0 |
| Prior VTE | 24.2 | 24.2 | 0 |
| Surgery within 2 wk prior to index event | 2.5 | 3.0 | −0.0367 |
| Thrombocytopenia | 6.8 | 5.7 | 0.0446 |
| . | Rivaroxaban, % . | LMWH, % . | Standardized difference . |
|---|---|---|---|
| Demographics | |||
| Age, median (25%, 75%), y* | 73 (68, 78) | 72 (68, 78) | — |
| Age ≥75 y | 42.2 | 40.6 | 0.0306 |
| Female sex | 74.7 | 71.3 | 0.0780 |
| White race | 80.2 | 80.7 | −0.0142 |
| Index event PE (with or without DVT) | 43.5 | 45.4 | −0.0381 |
| Index DVT only | 56.5 | 54.6 | 0.0381 |
| Primary cancer site | |||
| Breast | 36.9 | 35.0 | 0.0392 |
| Lung | 43.5 | 46.3 | −0.0572 |
| Ovary | 6.2 | 6.8 | −0.0235 |
| Pancreas | 10.2 | 8.7 | 0.0501 |
| Other | 3.2 | 3.2 | 0 |
| Cancer stage at diagnosis† | |||
| Stage, median (25%, 75%)* | 2 (2, 3) | 2 (2, 3) | — |
| Stage II or III | 98.9 | 0.0569 | |
| Stage I or IV or unknown | — | — | ‡ |
| Time from first cancer diagnosis to index VTE, y§ | |||
| Median (25%, 75%)* | 0.64 (0.13, 2.31) | 0.59 (0.13, 2.28) | — |
| <1 | 57.8 | 56.7 | 0.0229 |
| 1 to <2 | 13.0 | 14.6 | −0.045 |
| 2 to <3 | 9.5 | 7.8 | 0.0578 |
| ≥3 | 19.7 | 21.0 | −0.0331 |
| Comorbidities and medications | |||
| Active cancer therapy | 73.0 | 72.4 | 0.0128 |
| Antiplatelet use | 7.9 | 7.4 | 0.0208 |
| CKD stage 3 or worse | 32.5 | 32.9 | −0.0080 |
| Coagulopathy | 9.3 | 8.1 | 0.0392 |
| Major bleed | ‡ | ‡ | 0 |
| Prior VTE | 24.2 | 24.2 | 0 |
| Surgery within 2 wk prior to index event | 2.5 | 3.0 | −0.0367 |
| Thrombocytopenia | 6.8 | 5.7 | 0.0446 |
N = 529 in both groups.
CKD, chronic kidney disease; DVT, deep vein thrombosis.
Continuous variable not included in the propensity score model in lieu of the categorized version.
Stages I, II, III, and IV and unknown were separately included in the propensity score model.
Data not reported or reported for the entire study cohort, to comply with the Cell Size Suppression Policy of the Centers for Medicare and Medicaid Services (available at: https://www.resdac.org/articles/cms-cell-size-suppression-policy). Variables were included in the propensity score–matching algorithm, as depicted in the table.
Patients may have had subsequent relapse or new metastatic disease.